Home  |  Top News  |  Most Popular  |  Video  |  Multimedia  |  News Feeds  |  Feedback
  Medicine  |  Nature & Earth  |  Biology  |  Technology & Engineering  |  Space & Planetary  |  Psychology  |  Physics & Chemistry  |  Economics  |  Archaeology
Top > Medicine, Health Care > Genetically-engineered Preclinical Models Predict Pharmacodynamic… >

Genetically-engineered Preclinical Models Predict Pharmacodynamic Response

Published: September 19, 2012.
Released by University of North Carolina Health Care  

New cancer drugs must be thoroughly tested in preclinical models, often in mice, before they can be offered to cancer patients for the first time in phase I clinical trials. Key components of this process include pharmacokinetic and pharmacodynamic studies, which evaluate how the drug acts on a living organism. These studies measure the pharmacologic response and the duration and magnitude of response observed relative to the concentration of the drug at an active site in the organism.

A new comparison of four different methodologies for pharmacokinetic and pharmacodynamic testing of the anti-melanoma agent carboplatin, demonstrates that genetically-engineered mouse models provide tumor delivery of drug most comparable to the response seen in melanoma patients.

"These studies are critically important in the case of small-molecule cancer drugs, which often have systemic side effects and can be toxic at high concentrations," said Ned Sharpless, MD, Wellcome Distinguished Professor of Cancer Research and study co-author.

The study, led by Bill Zamboni, PharmD and PhD, Associate Professor of Pharmacotherapy and Experimental Therapeutics at the UNC Eshelman School of Pharmacy and a member of UNC Lineberger Comprehensive Cancer Center, and Ned Sharpless, MD, who is also Associate Director for Translational Research at UNC Lineberger.

The collaborative study, which appears in The Oncologist, brought together a set of unique resources available at UNC to determine which preclinical models best predict delivery of carboplatin to melanoma tumors in patients. "We have a unique opportunity to evaluate an important factor in the treatment of solid tumors because of the outstanding collaborative nature and novel resources at UNC", said Zamboni.

"We have used a pharmacokinetics testing method called microdialysis, which uses a tiny probe to take samples that measure serial drug concentrations in a tumor over time," he added. "We plan to use this method to advance pharmacology studies of anticancer agents in tumors and tissues of patients and to evaluate the tumor delivery of nanoparticles and other classes of delivery agents."

The team used the resources of the preclinical phase I unit at UNC Lineberger to compare how pharmacokenetic levels vary in several preclinical tumor models including a genetically-engineered model, a model where tumor cells are transplanted to the appropriate part of the body (called an orthotopic syngeneic transplant or OST), and a xenograft model, where human tumor tissue is transplanted.

"Because carboplatin is widely used, we have good data on how the drug works pharmacokenetically in humans. For the first time, we were able to compare these various laboratory techniques used in countless labs and the pharmaceutical industry to evaluate how carboplatin was delivered to the tumor and compare it to actual human data. None of these laboratory models are perfect, but the genetically-engineered model is the best in terms of predicting the amount of drug that is delivered to the tumor in human patients," Zamboni added.

"We know that laboratory models are imperfectly predictive of human response and if the tumor models don't predict delivery, they are most likely not an optimal research tools," he noted.

Sharpless added, "We are continually looking for ways to build better laboratory models so that new therapies move from the lab to the patient as quickly and safely as possible. This study provides valuable validation that genetically-engineered models can help us accomplish this objective."




The above story is based on materials provided by University of North Carolina Health Care.

Translate this page: Chinese French German Italian Japanese Korean Portuguese Russian Spanish


comments powered by Disqus


Related »

Drug 
10/12/10 
Fox Chase Researchers Uncover Achilles' Heel in Aggressive Breast Tumors
PHILADELPHIA (October 12, 2010)—In an unexpected twist, Fox Chase Cancer Center researchers find that the loss of a single …
Tumor 
5/5/11 
Hitting Target in Cancer Fight Now Easier with New Nanoparticle Platform, UCLA Scientists Say
The ability to use nanoparticles to deliver payloads of cancer-fighting drugs to tumors in the body could herald a …
Drug 
4/18/12 
Good Vibrations in Fight Against Cancer
Medicine-toting nanochains slip into tumors and explode a chemotherapy drug into hard-to-reach cores of cancer, engineers and scientists at …
Drugs 
3/30/11 
New 'Nanodrug' Breaks Down Barriers to Attack Breast Cancer Cells from the Inside Out
LOS ANGELES (March 29, 2011) – Throwing stones at castle walls is one way to attack an enemy, but …
Tumor 
1/14/13 
Fox Chase Researchers Discover Novel Role of the NEDD9 Gene in Early Stages of Breast Cancer
PHILADELPHIA, PA (January 14, 2013)—Breast cancer is the second leading cause of cancer deaths among women in the United …
Drug 
4/15/13 
UCLA Researchers Find Nanodiamonds Could Improve Effectiveness of Breast Cancer Treatment
Recently, doctors have begun to categorize breast cancers into four main groups according to the genetic makeup of the …
Visible 
5/15/14 
Going Beyond the Surface
BUFFALO, N.Y. -- Photodynamic therapy (PDT) is an effective treatment for easily accessible tumors such as oral and skin …
More » 
 
© Newsline Group  |  About  |  Privacy Policy  |  Feedback  |  Mobile